News
EMA accepts Mundipharma’s application for candidiasis drug rezafungin
The European Medicines Agency (EMA) has accepted Mundipharma’s marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adults.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The European Medicines Agency (EMA) has accepted Mundipharma’s marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adults.